Crossmark

A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers

Crossref DOI link: https://doi.org/10.1186/s12890-018-0763-9

Published Online: 2019-01-07

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Staton, Tracy L.

Peng, Kun

Owen, Ryan

Choy, David F.

Cabanski, Christopher R.

Fong, Alice

Brunstein, Flavia

Alatsis, Kathila R.

Chen, Hubert
Funding

Funding for this research was provided by:

Genentech
License Information

Text and Data Mining valid from 2019-01-07
More Information

Article History

Received: 28 August 2018

Accepted: 10 December 2018

First Online: 7 January 2019

Ethics approval and consent to participate

: This study was conducted in full conformance with the International Conference on Harmonization (ICH) E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki. The study was conducted in the United States under an Investigational New Drug (IND) application in compliance with U.S. Food and Drug Administration (FDA) regulations. The Crescent City Institutional Review Board (New Orleans, LA) granted approval for this study. All subjects and patients provided written, informed consent. This manuscript adheres to the CONSORT guidelines (ExternalRef removed/) for the reporting of clinical trials.

: Not applicable.

: All authors were employees of Genentech, Inc. a member of the Roche group, at the time this study was performed and own Roche stock and/or stock options.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below